Portal de Periódicos da CAPES

Reversible skin and hair depigmentation during chemotherapy with dasatinib for chronic myeloid leukemia

2015; Wiley; Volume: 43; Issue: 1 Linguagem: Inglês

10.1111/1346-8138.13150

1346-8138

Akihito Fujimi, Soushi Ibata, Yuji Kanisawa, Takanori Shibata, Hiroki Sakamoto, Shota Yamada, Toshinori Okuda, Sho Takahashi, Shinya Minami, Akari Hashimoto,

Chemotherapy-related skin toxicity

The Journal of DermatologyVolume 43, Issue 1 p. 106-107 Letter to the Editor Reversible skin and hair depigmentation during chemotherapy with dasatinib for chronic myeloid leukemia Akihito Fujimi, Corresponding Author Akihito Fujimi Department of Hematology and Oncology, Oji General Hospital, Tomakomai, JapanCorrespondence: Akihito Fujimi, M.D., Ph.D., Department of Hematology and Oncology, Oji General Hospital, 3-4-8 Wakakusa-cho, Tomakomai City, Hokkaido 053-8506, Japan. Email: [email protected]Search for more papers by this authorSoushi Ibata, Soushi Ibata Department of Hematology and Oncology, Oji General Hospital, Tomakomai, JapanSearch for more papers by this authorYuji Kanisawa, Yuji Kanisawa Department of Hematology and Oncology, Oji General Hospital, Tomakomai, JapanSearch for more papers by this authorTakanori Shibata, Takanori Shibata Department of Gastroenterology, Oji General Hospital, Tomakomai, JapanSearch for more papers by this authorHiroki Sakamoto, Hiroki Sakamoto Department of Gastroenterology, Oji General Hospital, Tomakomai, JapanSearch for more papers by this authorShota Yamada, Shota Yamada Department of Gastroenterology, Oji General Hospital, Tomakomai, JapanSearch for more papers by this authorToshinori Okuda, Toshinori Okuda Department of Gastroenterology, Oji General Hospital, Tomakomai, JapanSearch for more papers by this authorSho Takahashi, Sho Takahashi Department of Gastroenterology, Oji General Hospital, Tomakomai, JapanSearch for more papers by this authorShinya Minami, Shinya Minami Department of Gastroenterology, Oji General Hospital, Tomakomai, JapanSearch for more papers by this authorAkari Hashimoto, Akari Hashimoto Department of Medical Oncology and Hematology, Sapporo Medical University, Sapporo, JapanSearch for more papers by this author Akihito Fujimi, Corresponding Author Akihito Fujimi Department of Hematology and Oncology, Oji General Hospital, Tomakomai, JapanCorrespondence: Akihito Fujimi, M.D., Ph.D., Department of Hematology and Oncology, Oji General Hospital, 3-4-8 Wakakusa-cho, Tomakomai City, Hokkaido 053-8506, Japan. Email: [email protected]Search for more papers by this authorSoushi Ibata, Soushi Ibata Department of Hematology and Oncology, Oji General Hospital, Tomakomai, JapanSearch for more papers by this authorYuji Kanisawa, Yuji Kanisawa Department of Hematology and Oncology, Oji General Hospital, Tomakomai, JapanSearch for more papers by this authorTakanori Shibata, Takanori Shibata Department of Gastroenterology, Oji General Hospital, Tomakomai, JapanSearch for more papers by this authorHiroki Sakamoto, Hiroki Sakamoto Department of Gastroenterology, Oji General Hospital, Tomakomai, JapanSearch for more papers by this authorShota Yamada, Shota Yamada Department of Gastroenterology, Oji General Hospital, Tomakomai, JapanSearch for more papers by this authorToshinori Okuda, Toshinori Okuda Department of Gastroenterology, Oji General Hospital, Tomakomai, JapanSearch for more papers by this authorSho Takahashi, Sho Takahashi Department of Gastroenterology, Oji General Hospital, Tomakomai, JapanSearch for more papers by this authorShinya Minami, Shinya Minami Department of Gastroenterology, Oji General Hospital, Tomakomai, JapanSearch for more papers by this authorAkari Hashimoto, Akari Hashimoto Department of Medical Oncology and Hematology, Sapporo Medical University, Sapporo, JapanSearch for more papers by this author First published: 05 October 2015 https://doi.org/10.1111/1346-8138.13150Citations: 8Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Rosenbaum SE, Wu S, Newman MA, West DP, Kuzel T, Lacouture ME. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer 2008; 16: 557–566. 2Boudadi K, Chugh R. Diffuse hypopigmentation followed by hyperpigmentation in an african american woman with hemangiopericytoma treated with dasatinib. J Clin Diagn Res 2014; 8: QD01–QD02. 3Brazzelli V, Grasso V, Barbaccia V et al. Hair depigmentation and vitiligo-like lesions in a leukaemic paediatric patient during chemotherapy with dasatinib. Acta Derm Venereol 2012; 92: 218–219. 4Sun A, Akin RS, Cobos E, Smith J. Hair depigmentation during chemotherapy with dasatinib, a dual Bcr-Abl/Src family tyrosine kinase inhibitor. J Drugs Dermatol 2009; 8: 395–398. 5Samimi S, Chu E, Seykora J et al. Dasatinib-induced leukotrichia in a patient with chronic myelogenous leukemia. JAMA Dermatol 2013; 149: 637–639. Citing Literature Volume43, Issue1Special Issue: Understanding the pathogenesis and developing new therapy of systemic sclerosis (pages 1‐69)January 2016Pages 106-107 ReferencesRelatedInformation